Quick Answer
Q32 Bio Inc. reported Total Revenue of $53.74 million for fiscal year 2025.
Q32 Bio Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $53.74M | $0.00 +100.0% |
-$6.65M -307.3% |
$3.21M -90.6% |
$33.97M +1157.3% |
$2.70M +62.2% |
| Revenue (ASC 606) | — | — | $1.16M -64.0% |
$3.21M -90.6% |
$33.97M +1157.3% |
$2.70M +62.2% |
| Net Income | $29.82M +162.5% |
-$47.73M +11.2% |
-$53.74M -973.8% |
-$5.00M +94.8% |
-$95.76M +25.6% |
-$128.69M -23.8% |
| Diluted EPS | $2.42 +136.8% |
-$6.58 +95.7% |
-$153.96 -170966.7% |
-$0.09 +94.8% |
-$1.73 | — |
| Total Assets | $61.78M -33.1% |
$92.33M +96.2% |
$47.06M -79.4% |
$228.47M +7.9% |
$211.72M -19.7% |
$263.74M -15.1% |
| Cash and Equivalents | $48.30M -38.1% |
$77.97M +204.3% |
$25.62M -24.6% |
$33.99M -68.6% |
$108.38M -50.2% |
$217.43M +304.3% |
| Stockholders Equity | $42.01M +640.3% |
$5.67M +103.1% |
-$182.92M -39.9% |
-$130.71M -177.0% |
$169.65M -13.4% |
$196.00M -24.2% |
| R&D Expense | $19.16M -60.2% |
$48.14M +51.7% |
$31.73M -67.7% |
$98.35M +5.7% |
$93.08M -7.3% |
$100.39M +12.3% |
| Operating Income | $16.90M +125.6% |
-$66.10M -37.0% |
-$48.26M +63.8% |
-$133.28M -38.9% |
-$95.95M +26.3% |
-$130.26M -18.5% |
| Shares Outstanding | 12.86M +5.4% |
12.20M +3292.3% |
359,569 -99.4% |
57.48M +0.6% |
57.15M +13.7% |
50.27M +11.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2023 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$7.39M | +58.0% | +22.1% |
| Diluted EPS | September 30, 2025 | -$0.60 | +58.9% | +23.1% |
| Total Assets | September 30, 2025 | $57.78M | -44.7% | -12.6% |
| Cash and Equivalents | September 30, 2025 | $49.04M | -44.9% | -10.6% |
| Stockholders Equity | September 30, 2025 | -$18.45M | -200.8% | -50.8% |
| R&D Expense | September 30, 2025 | $3.56M | -75.2% | -31.1% |
| Operating Income | September 30, 2025 | -$7.58M | +59.7% | +17.4% |
| Shares Outstanding | September 30, 2025 | 12.30M | +1.4% | +0.9% |
- Q32 Bio Inc. reported Total Revenue of $53.74 million for fiscal year 2025.
- Q32 Bio Inc. reported Revenue (ASC 606) of $1.16 million for fiscal year 2023.
- Q32 Bio Inc. showed a decrease of -64.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Q32 Bio Inc. reported Net Income of $29.82 million for fiscal year 2025.
- Q32 Bio Inc. showed an increase of +162.5% in Net Income compared to the prior fiscal year.
- Q32 Bio Inc. reported Diluted EPS of $2.42 per share for fiscal year 2025.
- Q32 Bio Inc. showed an increase of +136.8% in Diluted EPS compared to the prior fiscal year.
- Q32 Bio Inc. reported Total Assets of $61.78 million for fiscal year 2025.
- Q32 Bio Inc. showed a decrease of -33.1% in Total Assets compared to the prior fiscal year.
- Q32 Bio Inc. reported Cash and Equivalents of $48.30 million for fiscal year 2025.
- Q32 Bio Inc. showed a decrease of -38.1% in Cash and Equivalents compared to the prior fiscal year.
- Q32 Bio Inc. reported Stockholders Equity of $42.01 million for fiscal year 2025.
- Q32 Bio Inc. showed an increase of +640.3% in Stockholders Equity compared to the prior fiscal year.
- Q32 Bio Inc. reported R&D Expense of $19.16 million for fiscal year 2025.
- Q32 Bio Inc. showed a decrease of -60.2% in R&D Expense compared to the prior fiscal year.
- Q32 Bio Inc. reported Operating Income of $16.90 million for fiscal year 2025.
- Q32 Bio Inc. showed an increase of +125.6% in Operating Income compared to the prior fiscal year.
- Q32 Bio Inc. reported Shares Outstanding of 12.86 million shares for fiscal year 2025.
- Q32 Bio Inc. showed an increase of +5.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: